A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

OBJECTIVE: To determine the current disease-modifying anti-rheumatic drug (DMARD) preferences of UK consultant rheumatologists. METHODS: A questionnaire was sent in May 2002. We asked which DMARD(s) was most frequently preferred first and sought the most typical sequence of DMARDs, including DMARD c...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Jobanputra, P, Wilson, J, Douglas, K, Burls, A
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	2004

Antzeko izenburuak

A SURVEY OF DMARD PREFERENCES OF UK RHEUMATOLOGISTS
nork: Douglas, K, et al.
Argitaratua: (2003)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
nork: T. Martijn Kuijper, et al.
Argitaratua: (2017-04-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
nork: Mysler E, et al.
Argitaratua: (2021-06-01)

When the first visit to the rheumatologist is established rheumatoid arthritis
nork: Taylor, P, et al.
Argitaratua: (2020)

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone
nork: Edwards, C, et al.
Argitaratua: (2008)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
nork: Michael D George, et al.
Argitaratua: (2021-04-01)

Periodontal Health as Perceived by Rheumatologists and Rheumatoid Arthritis Patients
nork: Natasha Proud, et al.
Argitaratua: (2023-04-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
nork: Maria Sergeevna Voronina, et al.
Argitaratua: (2012-10-01)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
nork: Kai Wei, et al.
Argitaratua: (2022-03-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
nork: Basant Kumar Maheshwari
Argitaratua: (2018-01-01)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation
nork: Jobanputra, P, et al.
Argitaratua: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
nork: Jobanputra, P, et al.
Argitaratua: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
nork: P. Jobanputra, et al.
Argitaratua: (2002-01-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
nork: Juthamas Prawjaeng, et al.
Argitaratua: (2023-05-01)

Rheumatoid arthritis seems to have DMARD treatment decision influenced by fibromyalgia
nork: Rafael Mendonça da Silva Chakr, et al.

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
nork: Barton, P, et al.
Argitaratua: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
nork: Barton, P, et al.
Argitaratua: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
nork: P Barton, et al.
Argitaratua: (2004-03-01)

A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference
nork: Hamre HJ, et al.
Argitaratua: (2018-03-01)

Elderly-onset rheumatoid arthritis: an outlook from a practicing rheumatologist
nork: Ch. Baimukhamedov
Argitaratua: (2020-09-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - Introduction
nork: Barton, P, et al.
Argitaratua: (2004)

Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis
nork: Laurette van Boheemen, et al.
Argitaratua: (2020-09-01)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
nork: Clark, W, et al.
Argitaratua: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
nork: Clark, W, et al.
Argitaratua: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
nork: Clark, W, et al.
Argitaratua: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
nork: W Clark, et al.
Argitaratua: (2004-09-01)

Individual DMARDs have different effects on the likelihood of developing septic arthritis in adults with rheumatoid arthritis
nork: Edwards, C, et al.
Argitaratua: (2005)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
nork: James Cheng-Chung Wei, et al.
Argitaratua: (2023-07-01)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
nork: Emiliano Marasco, et al.
Argitaratua: (2023-09-01)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
nork: Basiru Ahmad Zago, et al.
Argitaratua: (2020-12-01)

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
nork: Tillett, W, et al.
Argitaratua: (2020)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
nork: Hazan Karadeniz, et al.
Argitaratua: (2022-04-01)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
nork: Soo-Kyung Cho, et al.
Argitaratua: (2017-12-01)

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
nork: Esteban A. Gomez, et al.
Argitaratua: (2020-10-01)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
nork: Seogsong Jeong, et al.
Argitaratua: (2022-07-01)

Challenges in implementing treat-to-target in rheumatoid arthritis: a perspective from Brazilian rheumatologists
nork: Adriana Maria Kakehasi, et al.
Argitaratua: (2024-08-01)

Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making
nork: Bolge SC, et al.
Argitaratua: (2016-06-01)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
nork: Ruiz Garcia, V, et al.
Argitaratua: (2014)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
nork: Ruiz Garcia, V, et al.
Argitaratua: (2011)

To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis
nork: Delphine Bertrand, et al.
Argitaratua: (2024-02-01)